Summary
AmerisourceBergen Corporation (now Cencora, Inc.) announced on December 1, 2006, that it has acquired Access M.D., Inc. (AMD) for approximately $12.9 million in cash. AMD is a Canadian company specializing in services for manufacturers of specialty pharmaceuticals. This acquisition is a strategic move to expand AmerisourceBergen's presence in the specialty pharmaceutical services sector. The target company, AMD, is projected to generate around $6 million in revenues for the 2006 calendar year. Investors should view this as a bolt-on acquisition aimed at enhancing the company's capabilities and market reach within a growing segment of the pharmaceutical supply chain.
Key Highlights
- 1Acquisition of Access M.D., Inc. (AMD) by AmerisourceBergen Corporation.
- 2Transaction value of approximately $12.9 million in cash.
- 3AMD is a Canadian company providing services to specialty pharmaceutical manufacturers.
- 4AMD's projected calendar 2006 revenues are approximately $6 million.
- 5The acquisition aims to expand AmerisourceBergen's specialty pharmaceutical services capabilities.
- 6Filing made on December 1, 2006, reporting an event date of November 30, 2006.
Frequently Asked Questions
The primary purpose of this acquisition is to expand AmerisourceBergen's presence and capabilities within the specialty pharmaceutical services sector. By acquiring Access M.D., Inc. (AMD), the company is likely seeking to enhance its offerings to manufacturers of specialty drugs and strengthen its position in this niche market.
Access M.D., Inc. (AMD) is a relatively small acquisition in terms of revenue, with projected revenues of approximately $6 million for the 2006 calendar year. This suggests it's a strategic, rather than financially transformative, acquisition at this stage.
The acquisition cost AmerisourceBergen approximately $12.9 million in cash. Given the size of AMD's projected revenues, this appears to be a focused investment to gain specific expertise or market access in the specialty pharmaceutical services area, rather than a significant drain on resources.
Specialty pharmaceuticals are typically high-cost, complex biologic or biotech drugs that require special handling, storage, and administration. The market for these drugs is growing rapidly, and services supporting their manufacturers are crucial for effective distribution and patient access. AmerisourceBergen's interest in AMD indicates a strategic focus on this important and expanding segment of the healthcare industry.